Onconova Therapeutics Inc
ONTX
$0.69
Closing
▼-3.03%
1D
▼-7.99%
YTD
Market cap
$17.60M
52 week high
$1.43
52 week low
$0.55
Volume
6,186
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$17.60M
Analysts' Rating
STRONG BUY
Price Target (Mean)
7.5
Total Analysts
4
P/E
Operating Margin
-8928.07%
Beta
1.44
Revenue Growth (Annual)
0.00%
52 week high
$1.43
52 week low
$0.55
Div. Yield
%
EPS Annual Growth
15.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK’s), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. It is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
